Drug Trial Radar · NCT04127578
Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Jan 3, 2020
Primary completion
Aug 31, 2031
Study completion Aug 31, 2031
Sponsor
- Lead sponsor
- Prevail TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- Oct 15, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 35 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study J3Z-MC-OJAA is a Phase 1/2a, multicenter, open-label, ascending dose, first in-human study that will evaluate the safety of intracisternal LY3884961 administration in patients with moderate to severe Parkinson's disease with at least 1 pathogenic GBA1 mutation. Two dose level cohorts of LY3884961 are planned (Dose Level 1 and Dose Level 2). The duration of the study is 5 years. During the first year, patients will be evaluated for the effect of LY3884961 on safety, tolerability, immunogenicity, biomarkers, and clinical efficacy measures. Patients will continue to be followed for an additional 4 years to continue to monitor safety as well as selected biomarker and efficacy measures.
Conditions
- Parkinson Disease
Interventions
LY3884961Biological
Participants will receive a single dose of LY3884961, administered intra-cisterna magna
MethylprednisoloneDrug
6 IV pulses administered as concomitant medication over 3 months
SirolimusDrug
Back-up treatment if corticosteroid is not well tolerated. Loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative number of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: 5 years
- Incidence of procedure or treatment-emergent AEs measured by brain MRI, spine MRI and nerve conduction study (NCS)Time frame: 5 years
- Treatment emergent immunogenicity of AAV9 in bloodTime frame: Thru month 24
- Change from baseline in immunogenicity of AAV9 in bloodTime frame: Baseline and Month 24
- Treatment emergent immunogenicity of GCase in bloodTime frame: Thru Month 24
- Change from baseline in immunogenicity of GCase in bloodTime frame: Baseline and Months 24
- Treatment emergent immunogenicity of Nfl in bloodTime frame: Thru Month 24
- Change from baseline in immunogenicity of Nfl in bloodTime frame: Baseline and Month 24
- Treatment emergent immunogenicity of AAV9 in CSFTime frame: Thru Month 24
- Change in immunogenicity of AAV9 in CSFTime frame: Baseline and Month 12
- Treatment emergent immunogenicity of GCase in CSFTime frame: Thru Month 24
- Change in immunogenicity of GCase in CSFTime frame: Baseline, and Months 12
Locations
15 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic, 13400 E. Shea Boulevard
Scottsdale, Arizona
Esperanza Clinical, 25220 Hancock Avenue
Murrieta, California
Rocky Mountain Clinical Research - CenExel - PPDS, 701 East Hampden Avenue Suite 510
Englewood, Colorado
K2 Medical Research, 101 Southhall Lane, Suite 150
Maitland, Florida
PPD, 100 West Gore Street, Suite 202
Orlando, Florida
Northwestern University Feinberg School of Medicine, Dept. of Neurology, Parkinson's Disease & Movement Disorders Center, 710 N. Lake Shore Drive, 11th Floor
Chicago, Illinois
Mayo Clinic, 200 First Street SW
Rochester, Minnesota
Mount Sinai Beth Israel, 10 Union Square East, Suite 5H
New York, New York
Joan and Sanford I. Weill Department of Medicine, 525 E 68th Street
New York, New York
Hospital of the University of Pennsylvania, 330 S. 9th Street
Philadelphia, Pennsylvania
Vanderbilt University Medical Center, 1500 21st Avenue South Suite 2600
Nashville, Tennessee
Shaare Zedek Medical Center, 12 Shmuel Biet Street
Jerusalem, Israel
Hadassah Medical Center, Hadassah Ein Kerem, Dept. of Neurology, P.O. Box 12000
Jerusalem, Israel
Sheba Medical Center, Tel Hashomer
Ramat Gan, Israel
Tel Aviv Sourasky Medical Center, 6 Weizmann St.
Tel Aviv, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.